Mycovia Pharmaceuticals Selects AllianceRx as Exclusive Pharmacy For VIVJOA


Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, announced U.S. availability of VIVJOA™ (oteseconazole) capsules in 2022, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.

VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Mycovia’s patient support program, My VIVJOA, powered by vitaCare (a subsidiairy of GoodRx), is available through a comprehensive program designed to help patients with insurance coverage support, seamlessly applied savings and ongoing education. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for branded medications.

VitaCare helps patients understand and verify insurance coverage, identify available savings opportunities, assist providers in their communication with payors, and offer a seamless path for filling the VIVJOA prescription primarily through an appropriate mail order or local pharmacy partners.

Recently, AllianceRx Walgreens (AllianceRx) announced that Walgreens specialty pharmacy patients will now have exclusive access to VIVJOA®, through AllianceRx Walgreens Pharmacy, a subsidiary of Walgreens.

The addition of this medication brings Walgreens enterprise specialty’s number of limited distribution drugs to among the highest of specialty pharmacies in the U.S. Access to 240+ limited distribution drugs is available through Walgreens specialty pharmacy.

In addition to being an exclusive specialty pharmacy for VIVJOA, AllianceRx’s exclusive distribution drugs include:

  • Cystaran – topical ophthalmic drug from Leadiant Bioscience.
  • Lysodren (mitotane) is the only FDA-approved drug to treat inoperable, functional or nonfunctional adrenocortical carcinoma, a rare cancer of the adrenal glands.
  • Metopirone (metyrapone) is used as a diagnostic test for adrenocorticotropic hormone (ACTH) insufficiency and in the diagnosis of ACTH-dependent Cushing’s syndrome.  Both are manufactured by HRA Pharma Rare Diseases.